A 12 Weeks,Multi-center,Randomized,Double-blind,Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of LP-003 in Adult Patients With Inadequately Controlled Moderate to Severe Seasonal Allergic Rhinitis Despite the Current Recommended Therapies
Latest Information Update: 19 Dec 2025
At a glance
- Drugs LP 003 Longbio Pharma (Primary)
- Indications Seasonal allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors LongBio Pharma
Most Recent Events
- 15 Dec 2025 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 15 Dec 2025 Status changed from recruiting to completed.
- 26 Feb 2024 Results for efficacy and safety presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology